Adjuvant Herceptin / Trastuzumab Treatment Duration

A few years ago when Herceptin (trastuzumab) was launched for the early stage of Her2+ breast cancer, the timing of treatment was fixed at one year. Why one year? No clue. Just a consensus figure decided by a few oncology investigators.

At the European Oncology meeting held in the end of Sep 2012 – data from large studies were presented. The two main studies were comparing one year versus six months of Herceptin – this showed that probably one year is better than six months. The other study of one year versus two years showed that one is probably enough.

So the consensus a few years ago, was right. Twelve months is the magic figure (for now).


– taken from my older blog

Published by

Rohit Joshi

I am a doctor who helps people deal with cancer with diagnosis and management of the illness (chemotherapy, biological agents, immunotherapy and hormonal agents).

Leave a Reply

Your email address will not be published. Required fields are marked *